ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "health behaviors"

  • Abstract Number: 1680 • ACR Convergence 2023

    What Trade-offs Are Acceptable to Rheumatoid Arthritis Patients During Treatment Selection?

    Rieke Alten1, Juan carlos Nieto-Gonzalez2, Peggy Jacques3, Carlomaurizio Montecucco4, Robert Moots5, Helga Radner6, Sebastian Heidenreich7, Chiara Whichello7, Nicolas Krucien7, Monia Zignani8, Harald Vonkeman9 and Katrien Van Beneden10, 1Department of Internal Medicine and Rheumatology, Schlosspark Klinik, University Medicine Berlin, Berlin, Germany, 2Servicio de Reumatología, Hospital General Universitario Gregorio Marañón, Madrid, Spain, 3Department of Rheumatology and VIB Inflammation Research Center, University Hospital Ghent, Ghent, Belgium, 4Division of Rheumatology, University of Pavia and Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, 5Department of Rheumatology, Aintree University Hospital, Liverpool, United Kingdom, 6Department of Internal Medicine III, Division of Rheumatology, Medical University Vienna, Vienna, Austria, 7Patient-centred Research, Evidera Inc., London, United Kingdom, 8Medical Affairs, Galapagos GmbH, Basel, Switzerland, 9Department of Rheumatology, Medisch Spectrum Twente and University of Twente, Enschede, Netherlands, 10Medical Safety, Galapagos NV, Mechelen, Belgium

    Background/Purpose: Multiple RA therapies are available that differ in attributes such as mode of administration and benefit-risk profile. Challenging trade-offs are made during treatment selection…
  • Abstract Number: 2023 • ACR Convergence 2023

    Transition Readiness over Time in a Rheumatology Transition Clinic

    Background/Purpose: In 2018 we designed a Rheumatology Transition clinic to care for adolescent patients with autoimmune disease. We incorporate Health Care Transition curriculum (HCT) into…
  • Abstract Number: 2036 • ACR Convergence 2023

    Switch or Stay the Same? Preferences of People with Autoimmune Disease on Rituximab for Different Types of COVID-19 Vaccine Boosters

    Todd Wilson1, Paul R. Fortin2, Ines Colmegna3, Sonia Theriault4, Nathalie Amiable5, Alexandra Godbout5 and Glen Hazlewood1, 1University of Calgary, Calgary, AB, Canada, 2Centre ARThrite - CHU de Québec - Université Laval, Quebec City, QC, Canada, 3The Research Institute of the McGill University Health Centre, Montréal, QC, Canada, 4The Research Institute of the McGill University Health Centre, Montreal, QC, Canada, 5Centre ARThrite - CHU de Quebec - Universite Laval, Quebec City, QC, Canada

    Background/Purpose: COVID-19 vaccines are now being offered as regular boosters every 6-12 months for people with autoimmune rheumatic diseases, particularly for people on rituximab, where…
  • Abstract Number: 2038 • ACR Convergence 2023

    Impact of COVID-19 Pandemic on Preventative Health Screenings in Rheumatology Outpatients

    Minerva Nong1, Medha Barbhaiya2, Jonah Levine3, Vivian Bykerk4, Rachel Heise5 and Lisa Mandl2, 1Hospital for Special Surgery, New York, NY, 2Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, 3NYU Grossman School of Medicine, New York, NY, 4Department of Rheumatology, Hospital for Special Surgery, New York, NY, 5Department of Population Health Sciences, Weill Cornell Medicine, New York, NY

    Background/Purpose: The COVID-19 pandemic created significant barriers to accessing recommended preventative health screening. Patients already managing a chronic disease, particularly those using immunosuppressive medications, may…
  • Abstract Number: 2285 • ACR Convergence 2023

    Vaccine Uptake in Women with Systemic Lupus Erythematosus (SLE) – Study Update

    J. Patricia Dhar1, Hannah Forsythe2, Louis Saravolatz1 and Susanna Szpunar3, 1Ascension St. John Hospital and Wayne State University School of Medicine, Detroit, MI, 2Michigan Department of Human and Health Services, Lansing, MI, 3Ascension St. John Hospital, Detroit, MI

    Background/Purpose: Infections are a major cause of morbidity & mortality in patients with systemic lupus erythematosus (SLE), including vaccine-preventable infections. SLE patients are considered to…
  • Abstract Number: 0175 • ACR Convergence 2023

    Predicting Cost-Related Medication Non-Adherence in US Adults with Chronic Arthritis: A Machine Learning Approach

    Ashkan Ara1, Matthew Chenoweth1 and Christopher Scannell2, 1University of California Los Angeles, Los Angeles, CA, 2UCLA / West Los Angeles VA Medical Center, Los Angeles, CA

    Background/Purpose: Cost-related medication non-adherence (CRN) occurs when patients are unable to follow their prescribed medication regimen due to financial constraints, such as high costs or…
  • Abstract Number: 2291 • ACR Convergence 2023

    Therapeutic Drug Monitoring (TDM) of Hydroxychloroquine in Whole Blood: Analysis of over 10,000 Patient Results Using Lab Developed Liquid Chromatography Tandem Mass Spectrometry

    Jane Yang, Brett Holmquist, Rubio Punzalan and Kelly Chun, Labcorp, Calabasas, CA

    Background/Purpose: Hydroxychloroquine (HCQ), a mainstay SLE therapy, improves survival and reduces flares. Therapeutic drug monitoring (TDM) may be useful in 1) identifying and improving adherence…
  • Abstract Number: 0190 • ACR Convergence 2023

    Racial Disparities in Self-reported Extent and Reasons for Nonadherence in SLE

    Kai Sun1, Londyn Robinson2, Amanda Eudy3, Jennifer Rogers1, Rebecca Sadun1, Lisa Criscione-Schreiber4, Jayanth Doss1 and Megan Clowse5, 1Duke University, Durham, NC, 2University of Minnesota Medical School, Minneapolis, MN, 3Duke University, Raleigh, NC, 4Duke University School of Medicine, Durham, NC, 5Duke University, Chapel Hill, NC

    Background/Purpose: Medication nonadherence is common in SLE and disproportionately affects Black patients. Nonadherence leads to increased hospitalizations, morbidity, and mortality and is a modifiable factor…
  • Abstract Number: 2535 • ACR Convergence 2023

    Strategies to Embrace Living with Lupus Fearlessly (SELF): A Promising Digital Intervention for Lupus Self-Management

    Katherine Carpenter1, Melissa French2, Sarah Gilman3, Sara Johnson4, Patricia Castle4, S. Sam Lim5, Charmayne Dunlop-Thomas5, Melicent Miller1 and Mary Crimmings1, 1Lupus Foundation of America, Washington, DC, 2Lupus Foundation of America, Alexandria, VA, 3Wayfinder Health Strategies, Falls Church, VA, 4Pro-Change Behavior Systems, Inc., Narragansett, RI, 5Emory University, Atlanta, GA

    Background/Purpose: The Lupus Foundation of America (LFA) has engaged in a 5-year cooperative agreement with the Centers for Disease Control and Prevention to implement a…
  • Abstract Number: 0317 • ACR Convergence 2023

    Long-term Effectiveness of a Lifestyle Program for Osteoarthritis: One-year Follow-up of the “Plants for Joints” Randomized Clinical Trial

    Carlijn Wagenaar1, Wendy Walrabenstein1, Marike Van der Leeden2, Martijn Gerritsen2, Jos W.R. Twisk1, Martin van der Esch2, Henriët van Middendorp3, Peter Weijs4 and Dirkjan van Schaardenburg5, 1Amsterdam University Medical Centers, Amsterdam, Netherlands, 2Reade Rheumatology Center, Amsterdam, Netherlands, 3Leiden University, Leiden, Netherlands, 4Amsterdam University of Applied Sciences, Amsterdam, Netherlands, 5Reade, Amsterdam, Netherlands

    Background/Purpose: The 16-week Plants for Joints (PFJ) multidisciplinary lifestyle program, based on a whole-food plant-based diet, physical activity, and stress management, significantly reduced The Western…
  • Abstract Number: PP16 • ACR Convergence 2023

    Peer Health Coaches Help Scleroderma Patients Cope with Isolation

    Mary Alore1, Yen Chen2 and Susan Murphy3, 1Troy, MI, 2University of Michigan, Ann Arbor, MI, 3University of Michigan, Plymouth, MI

    Background/Purpose: In 2011, I felt extremely isolated with my new diagnosis of diffuse systemic sclerosis and sought support online and in support groups. In addition…
  • Abstract Number: 1087 • ACR Convergence 2023

    Characterizing Herpes Zoster Vaccination Patterns in Rheumatoid Arthritis Patients in a Tertiary Care Clinic: A Quality Improvement Approach

    Sara Faghihi-Kashani, Arooj Babar and Janice Lin, Stanford University, Palo Alto, CA

    Background/Purpose: Patients with rheumatoid arthritis (RA) face an increased risk of herpes zoster (HZ) infection, notably those on immunosuppressive therapy. Herpes zoster infection is associated…
  • Abstract Number: 1203 • ACR Convergence 2023

    Vaccination Against SARS-CoV-2 in Inflammatory Arthritis and Factors Determining Its Decision

    Olivier FAKIH1, Charlotte Bourgoin2, Violette Benier1, Thomas Lohse1, Cerise Guillochon1, Elodie Bouvier2, Jean-Charles Balblanc1, Thierry Conrozier1 and Anne Lohse1, 1Service de rhumatologie, Hôpital Nord Franche-Comté, Trévenans, France, 2Unité de recherche clinique, Hôpital Nord Franche-Comté, Trévenans, France

    Background/Purpose: DMARDs, which are essential for controlling the progression of inflammatory arthritis (IA), are mostly immunomodulators that significantly increase the risk of severe infections. Therefore,…
  • Abstract Number: 1262 • ACR Convergence 2023

    “Somebody Who’s Been There and Can Understand the Challenges That You’re Going Through”: Participant Perspectives of a Resilience-Based Energy Management Online Intervention for Systemic Sclerosis with Peer Health Coaches

    Yen Chen1, Alexandra Harper2, Tiffany Phanhdone3, Mary Alore1, Sheri Hicks1, Adam Pape1, Gina Jay1, Shannen Bolde1, Jennie Feldpausch1, Dinesh Khanna1 and Susan Murphy4, 1University of Michigan, Ann Arbor, MI, 2University of Michigan, Ypsilanti Charter Twp, MI, 3Northwestern University, Chicago, IL, 4University of Michigan, Plymouth, MI

    Background/Purpose: People with systemic sclerosis (SSc) often experience fatigue, which impacts daily life functioning and quality of life. We developed a 12-week, resilience-based energy management…
  • Abstract Number: 1331 • ACR Convergence 2023

    Long-term Effectiveness of a Lifestyle Program for Rheumatoid Arthritis: One-year Follow-up of the “Plants for Joints” Randomized Clinical Trial

    Carlijn Wagenaar1, Wendy Walrabenstein1, Marike Van der Leeden2, Franktien Turkstra2, Jos W.R. Twisk1, Maarten Boers1, Henriët van Middendorp3, Peter Weijs4 and Dirkjan van Schaardenburg5, 1Amsterdam University Medical Centers, Amsterdam, Netherlands, 2Reade Rheumatology Center, Amsterdam, Netherlands, 3Leiden University, Leiden, Netherlands, 4Amsterdam University of Applied Sciences, Amsterdam, Netherlands, 5Reade, Amsterdam, Netherlands

    Background/Purpose: The 16-week Plants for Joints (PFJ) multidisciplinary lifestyle program, based on a whole-food plant-based diet, physical activity, and stress management, significantly reduced 28-joint Disease…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 9
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology